These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. All may not be meeting the eye. Archambault GF Hosp Formul; 1975 Aug; 10(8):414. PubMed ID: 10237848 [No Abstract] [Full Text] [Related]
5. Generic vs. brand name drugs--patients, pharmacists, physicians: caught in the middle. Felch WC Internist; 1979 May; 20(4):3-5. PubMed ID: 10242131 [No Abstract] [Full Text] [Related]
6. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
7. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development. Matthews JH Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357 [TBL] [Abstract][Full Text] [Related]
8. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
9. Veterinary drug availability. Gloyd J J Am Vet Med Assoc; 1980 Apr; 176(7):611-4. PubMed ID: 7372533 [No Abstract] [Full Text] [Related]
10. Dietary supplements: background for dialogue between the industry and the medical profession. Friede AI Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719 [No Abstract] [Full Text] [Related]
11. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
12. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
13. Extra-label drug use--pharmaceutical industry view. Welser JR J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571 [No Abstract] [Full Text] [Related]
14. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy. Paul SH Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270 [No Abstract] [Full Text] [Related]
15. The "Long" amendment. Provost GP Am J Hosp Pharm; 1967 Dec; 24(12):665. PubMed ID: 6073365 [No Abstract] [Full Text] [Related]
16. Adoption of orphan products by the pharmaceutical industry. Finkel MJ N Engl J Med; 1984 Sep; 311(10):677-8. PubMed ID: 6472354 [No Abstract] [Full Text] [Related]
17. Brand-name drug companies fail to meet R&D commitments. Kondro W CMAJ; 2006 Aug; 175(4):344. PubMed ID: 16908891 [No Abstract] [Full Text] [Related]
18. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
19. APhA government affairs annual report. Am Pharm; 1987 Feb; NS27(2):35-8. PubMed ID: 3565249 [No Abstract] [Full Text] [Related]
20. An overview of current programs on drug development and regulation for small ruminants--pharmaceutical industry perspective. Terry M Vet Hum Toxicol; 1993; 35 Suppl 2():12-3. PubMed ID: 8236759 [No Abstract] [Full Text] [Related] [Next] [New Search]